MDGL — Expected Completion of Phase 3 Study for MGL-3196 (Resmetirom) in NASH and Fibrosis
Jan 1, 2028, 5:00:00 AM UTC
Summary
Madrigal Pharmaceuticals, Inc. is expected to complete its Phase 3 clinical trial evaluating MGL-3196 (Resmetirom) for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis by January 1, 2028. The study involves over 1750 patients, focusing on those with fibrosis scores of F2 and F3, assessing both efficacy and safety. MGL-3196 aims to address significant unmet needs in NASH, a liver condition that can lead to serious complications like cirrhosis and liver cancer, potentially affecting a large patient population and indicating substantial market potential for effective treatments.
Company
MADRIGAL PHARMACEUTICALS INC (MDGL)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.madrigalpharma.comSimilar Events
Completion of Phase 3 Study on Resmetirom for NASH Cirrhosis
Madrigal Pharmaceuticals, Inc. announced the expected completion date of its Phase 3 study on resmetirom for patients with well-compensated NASH cirrhosis, set for January 1, 2027. The trial, titled MAESTRO-NASH-OUTCOMES, is a multi-national, double-blind, randomized, placebo-controlled study aimed at evaluating resmetirom's efficacy in reducing liver-related and cardiovascular mortality among patients. The study involves 700 participants and includes both treatment and placebo groups. Results could significantly impact the development and marketability of resmetirom in addressing NASH cirrhosis, a severe liver condition.
clinical trial completionCompletion of Phase 3 Study of Resmetirom in NAFLD (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals, Inc. announced the completion of its Phase 3 study for Resmetirom in patients with nonalcoholic fatty liver disease (NAFLD). This critical trial, known as MAESTRO-NAFLD-OLE, aims to assess the efficacy and safety of Resmetirom, a selective thyroid hormone receptor beta agonist, that targets underlying causes of NAFLD. The results have the potential to significantly impact the company's position in the liver disease treatment market, depending on outcomes and subsequent regulatory approvals. The study's completion is a vital step toward advancing Resmetirom towards commercialization, benefiting patients with this prevalent condition that often leads to severe liver complications.
Clinical Trial CompletionExpected Completion of Clinical Trial for Efruxifermin in NASH/MASH Patients
Akero Therapeutics, Inc. is expected to complete its clinical trial evaluating efruxifermin in patients with compensated cirrhosis due to NASH/MASH by October 1, 2029. The trial, which aims to enroll 1,150 subjects, is being conducted as a multi-center, randomized, double-blind, placebo-controlled study. Efruxifermin is in Phase 3 of development and targets a growing market of non-alcoholic steatohepatitis (NASH), a chronic liver condition that poses significant health risks. The outcome of this trial could materially impact the company's pipeline and future revenue potential.
Clinical Trial Completion DateExpected Completion of Clinical Trial for Efruxifermin in NASH/MASH Patients
Akero Therapeutics, Inc. expects the completion of its Phase 3 clinical trial evaluating efruxifermin in patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis, scheduled for November 1, 2032. The study aims to enroll a total of 1,650 participants across two cohorts. As the trial is currently recruiting, positive outcomes could significantly impact the company's position in the treatment of liver diseases associated with metabolic disorders. For further details, visit the clinical trial page: https://www.clinicaltrials.gov/study/NCT06215716.
Expected Trial Completion